<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02817958</url>
  </required_header>
  <id_info>
    <org_study_id>UC-0160/1406</org_study_id>
    <secondary_id>AFU-GETUG 25</secondary_id>
    <secondary_id>2014-004678-41</secondary_id>
    <nct_id>NCT02817958</nct_id>
  </id_info>
  <brief_title>Evaluation of Lymphadenectomy and Chemotherapy TIP on Inguinal Lymph Nodes in Squamous Cell Carcinoma of the Penis</brief_title>
  <acronym>MEGACEP</acronym>
  <official_title>Prospective Phase II Study Evaluating a Multimodal Care of Inguinal Node Metastasis in Squamous Cell Carcinoma of the Penis by Bilateral Lymphadenectomy and Chemotherapy TIP</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>UNICANCER</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Squamous cell carcinoma of the penis is a rare tumor in Europe, whose prognosis and survival&#xD;
      are influenced by metastatic lymph node involvement. Its frequency in France is estimated at&#xD;
      less than 1% of human cancers. This spread follows a sequential process via the superficial&#xD;
      and deep inguinal lymph nodes and then to the pelvic lymph nodes before metastatic&#xD;
      dissemination.&#xD;
&#xD;
      The management of inguinal areas is the cornerstone of penile cancer. It is curative in about&#xD;
      80% of patients with 1 or 2 inguinal metastases. 5-years overall survival was on average 85%&#xD;
      for pN0 patients and 40% for pN+ patients. For pN+ patients, 5-year overall survival was 70&#xD;
      to 80% for pN1 (only 1 lymph node invasion), 30 to 40% for pN2, and 0 to 10% for pN3.&#xD;
&#xD;
      The risk of local recurrence is 5-10% for pN0 and 20-30% for pN+ after local treatment by&#xD;
      lymphadenectomy alone without chemotherapy. The average time to recurrence was 10 months.&#xD;
      Disease-free survival at 5 years is 75-85% for pN0 and 30-45% for pN+. Its indication depends&#xD;
      on clinical examination (presence or absence of lymph nodes palpated) and the risk of nodal&#xD;
      disease (≥pT1bG2).&#xD;
&#xD;
      Currently, a fine needle biopsy is the best clinical diagnosis method because it is a simple,&#xD;
      low risk, and possible in consultation. When the result is positive, it allows an early&#xD;
      dissection. Single or double fine needle biopsy will be used in cN+ patients. For patients at&#xD;
      risk of lymp nodes involvement (cN0 and ≥pT1B or G2), the sentinel node diagnosis may be&#xD;
      followed by modified or bilateral lymphadenectomy.&#xD;
&#xD;
      Although lymphadenectomy alone has a curator action, it sometimes remains insufficient in&#xD;
      patients with metastatic lymph node involvement. Therefore it seems important to develop a&#xD;
      multimodal approach in the management of these patients in order to increase the response&#xD;
      rate to treatment and survival.&#xD;
&#xD;
      From a Phase II trial conducted on 30 patients, the combination TIP (paclitaxel, ifosfamide,&#xD;
      and cisplatin) appears to have an efficacy / toxicity acceptable.&#xD;
&#xD;
      The TIP protocol has therefore been chosen for this trial as adjuvant or neo-adjuvant&#xD;
      treatment in patients with high risk of lymph nodes involvement (cN0 and ≥pT1B or G2), and&#xD;
      with inguinal mobile palpated lymph nodes (cN+) respectively, after lymph nodes involvement&#xD;
      proven (pN+).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 17, 2016</start_date>
  <completion_date type="Anticipated">September 2024</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>survival without locoregional lymph node recurrence</measure>
    <time_frame>24 months</time_frame>
    <description>checked by inguinal ultrasound</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete response rate for patients in neoadjuvant chemotherapy</measure>
    <time_frame>6 months</time_frame>
    <description>lack of residual tumor post surgical histopathology</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival without locoregional lymph node recurrence</measure>
    <time_frame>3 years</time_frame>
    <description>time between inclusion and locoregional recurrence or last evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival without metastasis</measure>
    <time_frame>3 years</time_frame>
    <description>time between inclusion and the date of occurrence of metastases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specific survival</measure>
    <time_frame>3 years</time_frame>
    <description>time between inclusion and date of death from penile cancer or treatment-related complication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years</time_frame>
    <description>time between inclusion and the death regardless of cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>3 years</time_frame>
    <description>Common Terminology Criteria for Adverse Events (CTCAE ) v4.03</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>1 year</time_frame>
    <description>questionnaire EORTC QLQ-C30 v3</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">37</enrollment>
  <condition>Penile Cancer</condition>
  <condition>Squamous Carcinoma</condition>
  <arm_group>
    <arm_group_label>A-Adjuvant Chemotherapy TIP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lymphadenectomy (+/- sentinel node) + adjuvant chemotherapy TIP modified bilateral lymphadenectomy 4 cycles every 21 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B-Neoadjuvant Chemotherapy TIP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>fine needle biopsy or sentinel node + neoadjuvant chemotherapy TIP followed by a lymphadenectomy modified bilateral lymphadenectomy 4 cycles every 21 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy TIP</intervention_name>
    <description>Paclitaxel, ifosfamide, and cisplatin</description>
    <arm_group_label>A-Adjuvant Chemotherapy TIP</arm_group_label>
    <arm_group_label>B-Neoadjuvant Chemotherapy TIP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. penile tumor histologically proven whatever the initial treatment of penile tumor:&#xD;
             amputation or conservative surgery or brachytherapy,&#xD;
&#xD;
          2. Mobile palpated lymph nodes (stage cN1 and cN2) whatever the T stage, Or If no&#xD;
             palpated lymph nodes (cN0), patients with nodes involvement risk ≥pT1b and / or Grade&#xD;
             2,&#xD;
&#xD;
          3. Metastatic lymph node involvement,&#xD;
&#xD;
          4. Patients M0 or Mx,&#xD;
&#xD;
          5. Age ≥18 ans,&#xD;
&#xD;
          6. Eastern Cooperative Oncology Group (ECOG) 0-1,&#xD;
&#xD;
          7. Leucocytes ≥1.5 g/L,&#xD;
&#xD;
          8. Hemoglobin ≥9 g/dL,&#xD;
&#xD;
          9. Platelets ≥100 000/mm³,&#xD;
&#xD;
         10. Normal calcemia and kaliemia,&#xD;
&#xD;
         11. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤1.5 upper limit&#xD;
             of normal (ULN) ; total bilirubin ≤1.5 ULN (3 ULN in case of Gilbert disease);&#xD;
             alkaline phosphatase (ALP) &lt;2 ULN,&#xD;
&#xD;
         12. Creatinine clearance ≥60 mL/min (MDRD method),&#xD;
&#xD;
         13. Left ventricular ejection fraction (LVEF) &gt;50%,&#xD;
&#xD;
         14. Patients having received, read the information note and signed consent,&#xD;
&#xD;
         15. Reproductive age patients agreeing to use two methods of birth control (one for the&#xD;
             patient and one for the partner) for the duration of the study and for 6 months after&#xD;
             the last dose of treatment,&#xD;
&#xD;
         16. Patients able to comply with the protocol requirements (scheduled visits, treatment&#xD;
             plan, clinical, paraclinical, biological and other procedures of the Protocol),&#xD;
&#xD;
         17. Patients undergoing a social security scheme.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Fixed inguinal lymph nodes (cN3),&#xD;
&#xD;
          2. Iliac lymph nodes (cN3),&#xD;
&#xD;
          3. Patients pN3,&#xD;
&#xD;
          4. prior chemotherapy for squamous cell carcinoma of the penis,&#xD;
&#xD;
          5. Against-indication for chemotherapy or known hypersensitivity to cisplatin, ifosfamide&#xD;
             or paclitaxel,&#xD;
&#xD;
          6. Patients treated with phenytoin,&#xD;
&#xD;
          7. Patients with hearing loss &gt;Grade 1 (CTCAE V4.03),&#xD;
&#xD;
          8. Patients with cardiopulmonary disease-indicating against overhydration,&#xD;
&#xD;
          9. History of cancer within 5 years prior to inclusion in the trial other than cutaneous&#xD;
             basal cell,&#xD;
&#xD;
         10. Patient received a live attenuated vaccine within 30 days prior to inclusion,&#xD;
&#xD;
         11. Patients already included in another clinical trial or receiving an experimental&#xD;
             treatment within 30 days prior to inclusion in the trial,&#xD;
&#xD;
         12. Patients deprived of their liberty or under court protection including guardianship,&#xD;
&#xD;
         13. Severe systemic disease or uncontrolled or any other chronic or acute illness that is&#xD;
             incompatible with the patient's participation in the trial according to investigator,&#xD;
&#xD;
         14. immunocompromised patients including with known seropositivity (HIV),&#xD;
&#xD;
         15. Patients with mental impairment which prevents the understanding of the protocol or&#xD;
             having a psychological state, family, sociological or geographical conditions that&#xD;
             would not allow compliance with the protocol and the planned follow-up or any&#xD;
             condition which, according to the investigator, would prevent participation patient&#xD;
             tested. These conditions should be assessed before inclusion of patients.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jérôme Rigaud, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Nantes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sandra PELISSIER</last_name>
    <phone>+33(0)144235568</phone>
    <email>s-pelissier@unicancer.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>ICO-Paul Papin</name>
      <address>
        <city>Angers</city>
        <zip>49055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Chr Besancon</name>
      <address>
        <city>Besançon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tristant MAURINA, Doctor</last_name>
      <phone>+33(0)3 81 66 93 67</phone>
      <email>t1maurina@chu-besancon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital SAINT ANDRE</name>
      <address>
        <city>Bordeaux</city>
        <zip>33075</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amaury DASTE, Doctor</last_name>
      <email>amaury.daste@chu-bordeaux.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre FRANCOIS BACLESSE</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florence JOLY, Prof</last_name>
      <phone>+33 2 31 45 50 02</phone>
      <email>f.joly@baclesse.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chru Gabriel Montpied</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent GUY, Professor</last_name>
      <phone>+33(0)4 73 75 14 97</phone>
      <email>lguy@chu-clermontferrand.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ch de Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aurélien DESCAZEAUD, Professor</last_name>
      <phone>+33(0)5 55 05 80 15</phone>
      <email>aurelien.descazeaud@chu-limoges.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aude FLECHON, Doctor</last_name>
      <phone>+33(0)4 78 78 26 43</phone>
      <email>aude.flechon@lyon.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chu Lyon Sud</name>
      <address>
        <city>Lyon</city>
        <zip>69310</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Etienne TERRIER, Dr</last_name>
      <phone>+33 4 72 67 88 01</phone>
      <email>jean-etienne.terrier01@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Paoli-Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gwenaelle GRAVIS, Doctor</last_name>
      <phone>+33(0)4 91 22 37 40</phone>
      <email>gravisg@ipc.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancerologie de Lorraine</name>
      <address>
        <city>Nancy</city>
        <zip>54519</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent MASSARD, Dr</last_name>
      <phone>+33 3 23 59 84 61</phone>
      <email>v.massard@nancy.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique Urologique- Chu Hotel Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jérôme RIGAUD, Professor</last_name>
      <phone>+33(0)2 40 08 39 10</phone>
      <email>jrigaud@chu-nantes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancerologie Du Gard - Centre Oncogard</name>
      <address>
        <city>Nîmes</city>
        <zip>300029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angélique CHAPELLE, Doctor</last_name>
      <phone>+33(0)4 30 06 10 14</phone>
      <email>a.chapelle@oncogard.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stéphane CULINE, Professor</last_name>
      <phone>+33(0)1 42 49 42 47</phone>
      <email>stephane.culine@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chu de Rouen</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian PFISTER, Professor</last_name>
      <phone>+33(0)2 32 88 81 63</phone>
      <email>christian.pfister@chu-rouen.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ICO-René Gauducheau</name>
      <address>
        <city>saint Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuelle BOMPAS, Doctor</last_name>
      <phone>+33(0)2 40 67 97 00</phone>
      <email>emmanuelle.bompas@ico.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe BARTHELEMY, Doctor</last_name>
      <email>philippe.barthelemy@chru-strasbourg.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 24, 2016</study_first_submitted>
  <study_first_submitted_qc>June 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2016</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>inguinal lymph nodes</keyword>
  <keyword>penile cancer</keyword>
  <keyword>squamous</keyword>
  <keyword>TIP chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Penile Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Individual Participant Data will not be shared at an individual level. Those data will be part of the study database including all enrolled patients.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

